Tag Archives: Cory Kasimov

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Tilray (NASDAQ: TLRY) and Aimmune Therapeutics (NASDAQ: AIMT)

Analysts fell to the sidelines weighing in on ACADIA Pharmaceuticals (ACAD – Research Report), Tilray (TLRY – Research Report) and Aimmune Therapeutics (AIMT – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the

Analysts Have Conflicting Sentiments on These Healthcare Companies: Editas Medicine (NASDAQ: EDIT) and Tactile Systems Technology (NASDAQ: TCMD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Editas Medicine (EDIT – Research Report) and Tactile Systems Technology (TCMD – Research Report). Editas Medicine (EDIT) In a report released yesterday, Cory

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN), Globus Medical (NYSE: GMED) and Endologix (NASDAQ: ELGX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN – Research Report), Globus Medical (GMED – Research Report) and Endologix (ELGX – Research Report). BioMarin Pharmaceutical (BMRN) J.P. Morgan analyst Cory

Analysts Offer Insights on Healthcare Companies: Acorda Therapeutics (NASDAQ: ACOR), Zimmer Biomet Holdings (NYSE: ZBH) and Insulet (NASDAQ: PODD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acorda Therapeutics (ACOR – Research Report), Zimmer Biomet Holdings (ZBH – Research Report) and Insulet (PODD – Research Report). Acorda Therapeutics (ACOR) In

Ultragenyx Pharmaceutical (RARE) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) on February 13 and set a price target of $76.00. The company’s shares closed last Monday at $61.13. According to TipRanks.com, Kasimov is a

Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Dexcom (NASDAQ: DXCM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report) and Dexcom (DXCM – Research Report). Incyte (INCY) J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Incyte on